Skip to main content
Clinical Trials/ISRCTN46722730
ISRCTN46722730Active, not recruiting未知

Helsinki Improved Transcranial magnetic stimulation vs treatment as usual for depression

Hospital District of Helsinki and Uusimaa0 sites80 target enrollmentStarted: June 1, 2021Last updated:

Trial Snapshot

Phase
未知
Status
Active, not recruiting
Sponsor
Enrollment
80

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1. Diagnosis of major depressive disorder (DSM-IV) as the principal diagnosis with Patient Health Questionnaire-9 score >14
  • 2. Inability to tolerate antidepressant medication or unresponsiveness to minimum of 2 months trial with adequate dose of antidepressant
  • 3. No change in antidepressive medication in four weeks prior to treatment

Exclusion Criteria

  • 1. Previous rTMS treatment
  • 2. Borderline personality features exceeding 7 points in McLean Screening Instrument for Borderline Personality Disorder, or other somatic or psychiatric conditions that likely interfere with recovery from depression with TMS (an unstable medical illness, substantial neurological illness, chronic pain, psychotic disorder or current psychotic symptoms, substance abuse or dependency within last 3 months, >2 mg lorazepine equivalents benzodiazepine use daily or any anticonvulsant, or lifetime history of non-response to an adequate course—ie, a minimum of eight treatments—of electroconvulsive therapy)
  • 3. Patients with safety risks including active suicidality, pregnancy, magnetic metal or leads in the upper body, or history of seizures

Investigators

Sponsor
Hospital District of Helsinki and Uusimaa

Similar Trials